FDA Clears Philips’ Breast Density Measurement Application
Philips received FDA clearance for the first spectral breast density measurement application.
The application is for use with Philips’ MicroDose SI full-field digital mammography system. It’s the first spectral breast density tool, meaning fat and glandular tissue can be differentiated to accurately measure volumentric density, according to the company.
The most frequently used method to determine breast density is a visual analysis of an image of the breast. The spectral breast density measurement allows a more objective measurement, according to the company.
The application works by measuring independently the glandularity and thickness in each pixel of the image to calculate the total volume and volumetric percentage of glandular tissue in the breast. The examination is then automatically assigned a MicroDose density score that correlates to BI-RADS, the manual method for determining density.
Philips’ spectral mammography is made possible by the photon counting technology that sorts photos into low- or high-energy categories, eliminating the need for two exposures, the company said. This allows for spectral imaging within the routine mammogram.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
